Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?

 
• By Cathy Kelly

Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.

After Impact On Cognition Finally Demonstrated In Phase III Trial, will FDA, CMS and sponsors have a meeting of the minds? • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Market Access

More from Pink Sheet